A synchronized dual drug delivery molecule targeting cancer stem cells in tumor heterogeneity and metastasis
- Kim, Ji Hyeon; Park, Jung Min; Jung, Eunsun; Lee, Jieun; Han, Jiyou; Kim, Yoon-Jae; Kim, Ji Young; Seo, Jae Hong; Kim, Jong Seung
- Issue Date
- Pergamon Press Ltd.
- Triple-negative breast cancer; Cancer stem cells; MDR1; Binary prodrug; Metastasis
- Biomaterials, v.289
- Journal Title
- Cancer stem-like cells (CSCs) represent a key barrier to successful therapy for triple-negative breast cancer (TNBC). CSCs promote the emergence of chemoresistance, triggering relapse and resulting in a poor prognosis. We herein present CDF-TM, a new small molecule-based binary prodrug conjugated with SN-38 and 3,4-difluorobenzylidene curcumin (CDF) that is specifically activated in hypoxic conditions. CDF-TM treatment significantly induced apoptosis in TNBC-derived 3D spheroids, accompanied with caspase-3 activation as well as the attenuation of tumor stemness with evidence of reduction in aldehyde dehydrogenase 1 (ALDH1) activity and the CD44high/CD24low phenotype. An in vivo orthotopic allograft model was used to investigate its effects on tumor growth and metastasis. The dissemination of CSCs from primary allografts was impaired by CDF-TM, along with inhibition of tumor growth via eradication of CSCs and downregulation of multidrug resistance 1 (MDR1). This new small molecule-based binary prodrug offers a novel therapeutic option for metastatic TNBC.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
- 3. Graduate School > Graduate School > 1. Journal Articles
- 4. Research institute > Cancer Institute > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.